Clinical trial NCT00491738 (phase 2, status: terminated)
Conditions: renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: bevacizumab, sunitinib, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CNC(=O)C1=C(SC2=CC=C3C(NN=C3\C=C\C3=CC=CC=N3)=C2)C=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly
    tolerated.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Signed Informed Consent Form

          -  Histologically confirmed metastatic RCC

          -  Measurable disease, as defined by RECIST

          -  Age ≥ 18 years

          -  ECOG performance status of 0 or 1

          -  Prior nephrectomy

          -  Ability and capacity to comply with study and follow-up procedures

        Exclusion Criteria:

          -  RCC with predominantly sarcomatoid features

          -  Prior systemic or adjuvant therapy for RCC

          -  Radiotherapy for RCC within 28 days prior to Day 1

          -  Prior treatment with bevacizumab, sunitinib, sorafenib, axitinib, thalidomide, or
             other similar agents

          -  Current need for dialysis

          -  Life expectancy of < 12 weeks

          -  Current, recent, or planned participation in an experimental drug study

          -  Inadequate organ function

          -  Active infection or fever > 38.5°C within 3 days of starting treatment

          -  History of other malignancies within 5 years prior to Day 1

          -  Any other medical conditions (including mental illness or substance abuse) deemed by
             the clinician to be likely to interfere with a patient's ability to provide informed
             consent, cooperate, or participate in the study, or to interfere with the
             interpretation of the results

          -  Inadequately controlled hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  New York Heart Association (NYHA) Class II or greater CHF

          -  History of myocardial infarction or unstable angina within 6 months prior to Day 1

          -  History of stroke or transient ischemic attack within 6 months prior to Day 1

          -  Known CNS disease except for treated brain metastasis

          -  Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent
             peripheral arterial thrombosis within 6 months prior to Day 1

          -  History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month
             prior to Day 1

          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of
             therapeutic anticoagulation)

          -  Major surgical procedure or anticipation of need for major surgical procedure during
             the course of the study

          -  Serious, non-healing wound; active ulcer; or untreated bone fracture

          -  Known hypersensitivity to any component of bevacizumab

          -  Pregnancy (positive pregnancy test) or lactation

          -  Current, ongoing treatment with full-dose warfarin